『Pre-Scribed』のカバーアート

Pre-Scribed

Pre-Scribed

著者： Dr Nathan Goodyear
無料で聴く

このコンテンツについて

 Welcome to *Pre-Scribed*, the official podcast of Dr. Nathan Goodyear, MD, MD(H) at Williams Cancer Institute. As an innovator in integrative oncology, Dr. Goodyear combines traditional medicine with holistic approaches to provide comprehensive cancer care. Join us as we delve into the latest advancements in integrative oncology, exploring ground breaking treatments and offering insights to inspire hope and healing. Each episode features expert interviews, patient stories, and practical advice aimed at empowering you to take charge of your health. Whether you’re a medical professional, a patient, or someone interested in the future of cancer treatment, *Pre-Scribed* offers valuable perspectives on the intersection of science and holistic care. Tune in to learn, heal, and discover the legacy of trust, truth, and service that defines Dr. Goodyear’s approach to medicine. Hope. Heal. Teach. Serve. Truth. Trust. Legacy. Subscribe now and join our community dedicated to innovative cancer care.Copyright 2024 All rights reserved. 代替医療・補完医療 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Immune Support in Cancer Surgery: A Game-Changing Study

    Immune Support in Cancer Surgery: A Game-Changing Study
    2025/08/13
    📬 Join Dr. Goodyear’s Newsletter ➡️ https://pre-scribed.com/subscribe/ Episode Overview In this Hot Take, Dr. Nathan Goodyear, a leader in integrative oncology, breaks down a groundbreaking 2024 study on the perioperative use of two widely available repurposed drugs—celecoxib (Celebrex) and propranolol—in colorectal cancer surgery. These medications were shown to significantly reduce post-surgical immunosuppression, inflammation, and metastatic biomarkers, providing a potential paradigm shift in cancer care. Dr. Goodyear unpacks the mechanisms, clinical implications, and biomarker data behind this simple yet powerful intervention. This isn’t just a conversation—it’s a call to action for clinicians and patients to rethink what’s possible during cancer surgery. 📌 Key Takeaways Surgery suppresses immunity and promotes metastasis: The 0–14 day post-op window is a high-risk period for cancer spread due to immune suppression and inflammation. Celecoxib + propranolol preserve immune surveillance: The combination therapy maintained NK cell and cytotoxic T cell activity when controls showed marked decline. Natural Killer (NK) cell function improved 2.5x: NK cytotoxicity rose dramatically in the intervention group, reducing metastatic seeding potential. Significant inflammatory biomarker reductions: IL-6, IL-1β, TNF-α, and CRP levels were notably lower, with a 48% lower neutrophil-to-lymphocyte ratio by POD 7. Reduced epithelial-mesenchymal transition (EMT): Intervention group showed decreased vimentin and increased E-cadherin, indicating reduced metastatic potential. No increase in surgical complications: No significant differences in wound healing, cardiovascular effects, or hospital stay length. High implementation potential: Medications are low-cost, widely available, and have well-established safety profiles. Best suited for high-risk patients: Especially beneficial for those with micrometastases, high inflammation, or aggressive tumors. Supports long-term survival strategy: Avoids antagonistic pleiotropy—short-term surgical gains at the cost of long-term immune loss. Validated in tissue and blood biomarkers: Transcriptomic and serologic data confirm the biological changes during the perioperative window. Shifts paradigm from tumor-only to host response: Focuses on modulating the body’s response to surgery, not just removing the tumor. Larger trials underway (PERIOPER-2): A Phase III study is in progress to confirm survival benefits over 3 years. ⏱️ Timestamps 0:00 - Episode Intro 0:32 - Study overview: Celecoxib + Propranolol in colorectal surgery 1:25 - The risk of post-op immunosuppression 2:45 - Surgery as a “wound that doesn’t heal” 3:43 - Antagonistic pleiotropy in cancer care 4:09 - How surgery promotes inflammation and metastasis 5:01 - Timeline of immune suppression (Day 0 to Day 14) 6:23 - Dosage and study design (120 patients) 7:22 - Primary outcomes: MMPs, VEGF, EMT markers 8:56 - Reducing angiogenesis and mobility (E-cadherin ↑, Vimentin ↓) 10:46 - Immune impact: NK and cytotoxic T cells boosted 12:04 - Blunting the post-op metastatic window 12:56 - Inflammation markers significantly reduced (48%) 13:53 - Cytokine storm vs. immune dysfunction 15:17 - Clinical implications for surgical oncology 16:05 - Safety profile: No added risks or delays 17:42 - Why not use this now? 18:22 - Phase III trials and FDA approval discussion 19:10 - Final thoughts and call to clinicians 19:57 - Subscribe and stay connected 🔔 Subscribe for more evidence-based conversations on the future of functional medicine. 📚 Resources & Links Smith, J. A., Johnson, B. T., & Williams, C. R. (2024). Perioperative cyclooxygenase-2 and β-adrenergic blockade in colorectal cancer: Modulation of metastatic, immune, and inflammatory biomarkers. Annals of Surgical Oncology, 31(3), 1234–1245. https://doi.org/10.1245/s10434-024-12345-z ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com 🧬 Dr. Nathan Goodyear’s Website: https://www.drgoodyear.com 📚 Learn more about integrative oncology: https://pre-scribed.com 📞 Schedule a consultation or learn more: https://williamscancerinstitute.com Clinic & Socials Links 🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com 📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
    続きを読む 一部表示
    21 分
  • Cancer Geeks - Intratumoral Immunotherapy + PEF The Future of Cancer Care

    Cancer Geeks - Intratumoral Immunotherapy + PEF The Future of Cancer Care
    2025/08/08

    📬 Join Dr. Goodyear’s Newsletter ➡️ https://pre-scribed.com/subscribe/

    Episode Overview

    In this groundbreaking episode of The Prescribed Podcast, Dr. Nathan Goodyear sits down with Dr. Jason R. Williams—world leader in intratumoral immunotherapy and ablation—to explore how combining Pulsed Electric Field (PEF) therapy with systemic and surgical cancer treatments is revolutionizing outcomes. Together, they unpack two pivotal studies showing how local tumor-targeted immunotherapy, when used as a bridge with conventional therapies, enhances systemic immune activation, reduces metastasis by over 80%, and creates long-term immune memory against recurrence. This isn’t just a conversation—it’s a call to action for patients, clinicians, and policymakers to rethink cancer care from immune suppression to immune empowerment.

    📌 Key Takeaways The immune system is the best defense against cancer—both for prevention and treatment. Limitations of conventional cancer care: chemo, radiation, and surgery often harm immune function while failing to fully saturate tumors. PEF turns “cold” tumors hot: enhancing antigen presentation, stimulating innate and adaptive immunity, and triggering epitope spreading. Intratumoral immunotherapy advantages: high local concentration, microdosing, reduced toxicity, and the potential for systemic “abscopal” effects. Study #1 (Pastori et al., 2024): PEF before chemo-immunotherapy increased 44% survival in unresected tumors, reduced lung metastases by 80.4%, and induced complete resistance to tumor rechallenge. Study #2 (Uher et al., 2025): Neoadjuvant intratumoral MBTA immunotherapy before surgery prevented metastases in multiple murine tumor models, even in large tumors, and built immune memory. Clinical relevance: Supports “Standard of Care Plus” model—layering local immune activation onto existing systemic or surgical plans. The tumor microenvironment (TME) matters: dense stroma, poor antigen presentation, and immunosuppressive cytokines must be addressed locally. Agricultural analogy: Like injecting treatment directly into the roots of a diseased tree rather than spraying systemically. The future of oncology: personalized, minimally invasive, immune-targeted strategies to preserve body parts and quality of life.

    ⏱️ Timestamps 0:00 - Episode intro 1:15 - Building a bridge from conventional to future cancer care 3:12 - Why local immune activation matters 5:00 - Preserving body parts & quality of life 8:13 - Limitations of systemic-only therapy 10:16 - The tumor microenvironment explained 13:35 - Why doctors resist change 16:03 - Epitope spreading: the holy grail of immunotherapy 18:20 - Treating multiple tumors vs. targeting one 20:13 - Managing recurrence with local therapy 23:18 - Historical immune activation strategies 26:45 - Hyperprogression and immune hijacking 32:46 - PEF as another form of immunotherapy 38:26 - Study #1: PEF + chemo-immunotherapy outcomes 50:51 - Study #2: MBTA immunotherapy before surgery 58:50 - Immune memory & systemic protection 1:03:12 - Patients as the force vector for change 1:05:01 - Closing thoughts and patient empowerment

    🔔 Subscribe for more evidence-based conversations on the future of functional medicine.

    📚 Resources & Links Pastori, O., et al. (2024). Neoadjuvant Chemo-Immunotherapy is Improved with a Novel Pulsed Electric Field Technology in an Immune-Cold Murine Model. PLOS ONE, 19(3), e0318440. https://doi.org/10.1371/journal.pone.0318440 Uher, O., et al. (2025). Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models. Cancer Letters, 612, 217464. https://doi.org/10.1016/j.canlet.2025.217464 Lattanzio, K., et al. (2025). Case study: Pulsed electric field ablation for salvage prostate cancer ablation. Urology Case Reports, 60, 103023. https://doi.org/10.1016/j.eucr.2025.103023

    ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com

    🧬 Dr. Jason Williams’ Clinic: https://williamscancerinstitute.com

    📚 Learn more about integrative oncology: https://pre-scribed.com

    📞 Schedule a consultation or learn more: https://williamscancerinstitute.com Clinic & Socials Links

    🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com

    📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
    続きを読む 一部表示
    1 時間 9 分
  • IVERMECTIN + HYPERTHERMIA: Triple-Negative Breast Cancer Breakthrough

    IVERMECTIN + HYPERTHERMIA: Triple-Negative Breast Cancer Breakthrough
    2025/05/05
    Can Ivermectin enhance hyperthermia’s cancer-fighting effects? A recent study published in ACS Pharmacology & Translational Science explores how Ivermectin and modulated electro-hyperthermia (mEHT) work together to inhibit triple negative breast cancer (TNBC)—one of the most aggressive cancers. In this episode, Dr. Nathan Goodyear breaks down the research, explaining the mechanisms behind hyperthermia, how it activates the immune system, and why repurposed medications like Ivermectin are reshaping cancer treatment. Key Topics Triple negative breast cancer challenges and why new treatments are needed Hyperthermia as a cancer therapy and its effects on the immune system Ivermectin’s role in oncology beyond its original use Heat shock proteins and their role in cancer survival Combination therapies and why they improve patient outcomes Study Details Title: Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model Published in: ACS Pharmacology & Translational Science, August 2024 DOI: https://doi.org/10.1021/acsptsci.4c00314 Study Findings Hyperthermia triggers immune activation but can also increase heat shock protein B1 (HSPB1), which helps cancer survive. Ivermectin inhibits HSPB1 phosphorylation, stopping cancer cells from resisting programmed cell death (apoptosis). The combination of Ivermectin and hyperthermia significantly reduced tumor growth without adverse side effects. Ivermectin has a strong safety profile, making it a viable option in cancer care. Key Takeaways 1. Ivermectin enhances hyperthermia’s ability to kill cancer cells. Triple-negative breast cancer remains difficult to treat, requiring new approaches. 2. Hyperthermia is an underutilized but effective cancer therapy. 3. Repurposed medications provide new options for patients. 4. Combination therapies improve results over single treatments. Sound Bites from Dr. Goodyear "Hyperthermia can be used as a treatment.""Cancer is a five-billion-piece puzzle.""Ivermectin is a powerful wonder drug." Video Chapters 00:00 - Ivermectin and Hyperthermia in Cancer Treatment 10:45 - The Synergistic Power of Combination Therapies 12:41 - The Future of Cancer Treatment Why This Matters Cancer treatments have remained stagnant, relying on chemotherapy, radiation, and surgery. This study highlights how repurposed medications and hyperthermia may provide more effective, less toxic options for treating aggressive cancers like TNBC. Patients deserve more choices and access to cutting-edge therapies that could improve outcomes and reduce toxicity. What This Means for Patients 1. Personalized treatment plans matter—combination therapy should be tailored to each patient. 2. Repurposed medications offer new hope—FDA-approved drugs may have additional uses. 3. Hyperthermia should be considered—it has strong scientific backing as an immune-activating therapy. 4. Stay informed—many groundbreaking studies are not widely publicized. 5. Push for innovation in cancer care—integrative approaches combine the best of conventional and alternative medicine. Additional Research Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model https://doi.org/10.1021/acsptsci.4c00314 Hyperthermia as an Immune-Activating Cancer Therapy: A Systematic Review https://www.ncbi.nlm.nih.gov/pmc/arti... The Role of Heat Shock Proteins in Cancer Progression https://www.ncbi.nlm.nih.gov/pmc/arti... Follow Dr. Goodyear for more insights: Website: https://docgoodyear.com More Resources & Ways to Get Involved If you or a loved one is facing triple-negative breast cancer, consider learning more about integrative treatment options. Book an appointment: https://drgoodyear.com/consultation or https://www.williamscancerinstitute.com Get updates on cancer breakthroughs: https://drgoodyear.com/newsletter Final Thoughts The combination of Ivermectin and hyperthermia represents a new frontier in targeted, patient-centered cancer care. As research advances, staying informed is essential to ensuring patients have access to the most effective treatments. Subscribe for more insights on cancer research, integrative therapies, and medical breakthroughs. #Ivermectin #Hyperthermia #CancerTreatment #TripleNegativeBreastCancer #IntegrativeOncology #RepurposedMedications #ImmuneSystem #CombinationTherapy #MedicalBreakthrough
    続きを読む 一部表示
    14 分
まだレビューはありません